{"schema_version":"secwatch.filing_event.v1","accession":"0001827635-26-000028","form_type":"8-K","ticker":"MANE","cik":"0001827635","company_name":"Veradermics, Inc","filed_at":"2026-08-11T12:15:58+00:00","discovered_at":"2026-08-11T12:20:10.341890+00:00","generated_at":"2026-08-11T12:20:16.722401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Veradermics Q2 net loss $23.5M; positive Phase 2 female hair-loss data, cash $819.9M","bullets":["Q2 2026 net loss $23.5M vs $15.6M YoY; R&D $18.6M (up $4.3M), G&A $10.9M (up $9.2M).","Phase 2 Study 207: mean TAHC increase 22.7 (QD) and 23.3 (BID) hairs/cm² at Month 6; 88.9%/90.0% improved on AAIRS.","Completed enrollment of Phase 2/3 Study 306 (556 female PHL patients); topline expected 1H27.","Phase 3 Study 304 topline and 12-month Study 302 data both anticipated in 2H26.","Cash $819.9M as of June 30, 2026; $472M raised in May 2026, funding into 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001827635-26-000028","json":"https://secwatch.observer/filing/0001827635-26-000028.json","markdown":"https://secwatch.observer/filing/0001827635-26-000028.md","text":"https://secwatch.observer/filing/0001827635-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/0001827635-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/mane-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:20:16.722401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}